NCT00518375View on ClinicalTrials.gov

Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus

PHASE4CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

April 30, 2000

Study Completion Date

May 31, 2001

Conditions

Kidney Transplantation

Interventions

DRUG

Rapamune® (Sirolimus)

DRUG

Neoral® (Cyclosporine)

DRUG

Corticosteroids

Left up to local practice but steroids are typically used perioperatively

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00518375 - Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus | Biotech Hunter | Biotech Hunter